ABCL
AbCellera Biologics Inc (ABCL)
Healthcare • NASDAQ • $11.80-6.94%
- Symbol
- ABCL
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $11.80
- Daily Change
- -6.94%
- Market Cap
- $3.82B
- Trailing P/E
- N/A
- Forward P/E
- -15.48
- 52W High
- $15.02
- 52W Low
- $2.75
- Analyst Target
- $16.82
- Dividend Yield
- 0.00%
- Beta
- 1.41
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to resea…
Company websiteResearch ABCL on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.